芪龙通络胶囊联合长春西汀对脑梗死患者神经功能、血管内皮功能及血液流变学的影响

摘要 目的：探讨芪龙通络胶囊联合长春西汀对脑梗死患者神经功能、血管内皮功能及血液流变学的影响。方法：选取2016年4月~2019年5月期间我院收治的脑梗死患者142例，上述患者根据随机数字表法分为对照组（n=71）和研究组（n=71），其中对照组患者给予长春西汀治疗，研究组则在对照组的基础上联合芪龙通络胶囊治疗，比较两组患者疗效、神经功能、血管内皮功能及血液流变学，记录两组治疗期间不良反应状况。结果：研究组治疗2周后的临床总有效率为90.14%（64/71），高于对照组患者的73.24%（52/71）（P<0.05）。两组治疗2周后美国国立卫生研究院卒中量表（NIHSS）评分、神经元特异性烯醇化酶（NSE）、内皮素 -1（ET-1）、全血黏度高切、全血黏度低切、血浆黏度、纤维蛋白原降低，且研究组低于对照组（P<0.05）；两组治疗2周后神经生长因子（NGF）、脑源性神经营养因子（BDNF）、血管内皮生长因子（VEGF）、一氧化氮（NO）升高，且研究组高于对照组（P<0.05）。两组不良反应发生率对比未见统计学差异（P>0.05）。结论：芪龙通络胶囊联合长春西汀治疗脑梗死患者的疗效显著，可有效改善患者神经功能、血管内皮功能及血液流变学，且不增加不良反应发生率。

Effect of Qilongtongluo Capsule Combined with Edaravone on Neurologic Function, Vascular Endothelial Function and Hemorheology in Patients with Cerebral Infarction

ABSTRACT Objective: To investigate the effect of qilongtongluo capsule combined with edaravone on neurologic function, vascular endothelial function and hemorheology in patients with cerebral infarction. Methods: 142 patients with cerebral infarction who were admitted to our hospital from April 2016 to May 2019 were selected, they were divided into control group (n=71) and study group (n=71) according to the random number table. The control group was treated with edaravone, and the study group was treated with qilongtongluo capsule on the basis of the control group. The curative effect, neurological function, vascular endothelial function and hemorheology of the two groups were compared, the adverse reactions of the two groups during the treatment were recorded. Results: The total clinical effective rate of the study group was 90.14% (64/71), which was higher than 73.24% (52/71) of the control group (P<0.05). 2 weeks after treatment, National Institutes of Health Stroke Scale (NIHSS) score, neuron specific enolase (NSE), endothelin-1 (ET-1), whole blood viscosity high cut, whole blood viscosity low cut, plasma viscosity and fibrinogen decreased, and those in the study group were lower than those in the control group (P<0.05). 2 weeks after treatment, Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and nitric oxide (NO) were elevated in both groups, and those in the study group were higher than those in the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Qilongtongluo capsule combined with edaravone has a significant therapeutic effect on patients with cerebral infarction, which can effectively improve the patient''s neurological function, vascular endothelial function and hemorheology, without increasing the incidence of adverse reactions.